Value of serum glycated albumin and high-sensitivity C-reactive protein levels in the prediction of presence of coronary artery disease in patients with type 2 diabetes

Cardiovascular Diabetology

Volumn 5, Issue , 2006, Pages

  Pu, Li Jin ^a   Lu, Lin ^a   Xu, Xue Wei ^a   Zhang, Rui Yan ^a   Zhang, Qi ^a   Zhang, Jian Sheng ^a   Hu, Jian ^a   Yang, Zheng Kun ^a   Ding, Feng Hua ^a   Chen, Qiu Jin ^a   Lou, Sheng ^a   Shen, Jie ^a   Fang, Dan Hong ^a   Shen, Wei Feng ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; GLUCOSE; GLYCOSYLATED ALBUMIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ORAL ANTIDIABETIC AGENT; URIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ALBUMIN BLOOD LEVEL; ANGIOCARDIOGRAPHY; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIAGNOSTIC VALUE; FEMALE; GENDER BIAS; GLUCOSE BLOOD LEVEL; HUMAN; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; UREA NITROGEN BLOOD LEVEL; URIC ACID BLOOD LEVEL;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; POSTPRANDIAL PERIOD; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; SERUM ALBUMIN;

EID: 33846639651     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-5-27     Document Type: Article

References (30)

1. Zellweger MJ Prognostic Significance of Silent Coronary Artery Disease in Type 2 Diabetes Herz 2006 31 240-245 10.1007/s00059-006-2790-1 16770561
2. Jandeleit-Dahm KA Lassila M Allen TJ Advanced glycation end products in diabetes-associated atherosclerosis and renal disease: Interventional studies Ann NY Acad Sci 2005 1043 759-766 10.1196/annals.1333.088 16037303
3. Pertynska-Marczewska M Kiriakidis S Wait R Beech J Feldmann M Paleolog EM Advanced glycation end products upregulate angiogenic and pro-inflammatory cytokine production in human monocyte/macrophages Cytokine 2004 28 35-47 10.1016/j.cyto.2004.06.006 15341924
4. Rendell M Paulsen R Eastberg S Stephen PM Valentine JL Smith CH Nierenberg J Rasbold K Klenk D Smith PK Clinical use and time relationship of changes in affinity measurement of glycosylated albumin and glycosylated hemoglobin Am J Med Sci 1986 292 11-14 10.1097/ 00000441-198607000-00002 3717201
5. Consensus development conference on the diagnosis of coronary artery disease in people with diabetes Diabetes Care American Diabetes Association 1998 21 1551-1559 9727908
6. Fornengo P Bosio A Epifani G Pallisco O Mancuso A Pascale C Prevalence of silent myocardial ischaemia in new-onset middle-aged Type 2 diabetic patients without other cardiovascular risk factors Diabet Med 2006 23 775-779 10.1111/j.1464-5491.2006.01910.x 16842483
7. Scholte AJ Bax JJ Wackers FJ Screening of asymptomatic patients with type 2 diabetes mellitus for silent coronary artery disease: Combined use of stress myocardial perfusion imaging and coronary calcium scoring J Nucl Cardiol 2006 13 11-18 10.1016/j.nuclcard.2005.11.002 16464712
8. Kharlip J Naglieri R Mitchell BD Ryan KA Donner TW Screening for silent coronary heart disease in type 2 diabetes: Clinical application of American Diabetes Association guidelines Diabetes Care 2006 29 692-694 10.2337/diacare.29.03.06.dc05-1374 16505528
9. Saely CH Koch L Schmid F Marte T Aczel S Langer P Hoefle G Drexel H Lipoprotein(a), type 2 diabetes and vascular risk in coronary patients Eur J Clin Invest 2006 36 91-97 10.1111/j.1365-2362.2006.01604.x 16436090
10. Mohan V Deepa R Haranath SP Premalatha G Rema M Sastry NG Enas EA Lipoprotein(a) is an independent risk factor for coronary artery disease in NIDDM patients in South India Diabetes Care 1998 21 1819-1823 9802727
11. O'Brien T Nguyen TT Harrison JM Bailey KR Dyck PJ Kottke BA Lipids and Lp(a) lipoprotein levels and coronary artery disease in subjects with non-insulin-dependent diabetes mellitus Mayo Clin Proc 1994 69 430-435 8170193
12. Pedreno J Fernandez R Ballester A Jornet A Uson M Canela J Petit M Lack of association of serum lipoprotein (a) levels with type-2 diabetes mellitus in patients with angiographically defined coronary artery disease Int J Cardiol 2000 74 159-167 10.1016/S0167-5273(00)00304-1 10962116
13. Jernkins AJ Best JD Klein RL Lyon TJ Lipoproteins, glycoxidation and diabetic angiopathy Diabetes Metab Res Rev 2004 20 349-368 10.1002/ dmrr.491 15343582
14. Varma R Garrick R McClung J Frishman WH Chronic renal dysfunction as an independent risk factor for the development of cardiovascular disease Cardiol Rev 2005 13 98-107 10.1097/01.crd.0000132600.45876.d0 15705261
15. Zhang RY Ni JW Zhang JS Hu J Yang ZK Zhang Q Lu AK Shen WF Long term clinical outcomes in patients with moderate renal insufficiency undergoing stent based percutaneous coronary intervention Chin Med J 2006 119 1176-1181 16863609
16. Higai K Shimamura A Matsumoto K Amadori-modified glycated albumin predominantly induces E-selectin expression on human umbilical vein endothelial cells through NADPH oxidase activation Clin Chim Acta 2006 367 137-143 10.1016/j.cca.2005.12.008 16455066
17. Cohen MP Ziyadeh FN Chen S Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: Pathogenic and therapeutic implications J Lab Clin Med 2006 147 211-219 10.1016/j.lab.2005.12.006 16697768
18. Cohen MP Intervention strategies to prevent pathogenetic effects of glycated albumin Arch Biochem Biophy 2003 419 25-30 10.1016/ j.abb.2003.08.012
19. Liu SX Hou FF Guo ZJ Nagai R Zhang WR Liu ZQ Zhou ZM Zhou M Xie D Wang GB Zhang X Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation Arterioscler Thromb Vasc Biol 2006 26 1156-1162 10.1161/ 01.ATV.0000214960.85469.68 16497990
20. Ehlermann P Eggers K Bierhaus A Most P Weichenhan D Greten J Nawroth PP Katus HA Remppis A Increased proinflammatory endothelial response to S100A8/A9 after preactivation through advanced glycation end products Cardiovasc Diabetol 2006 5 6 1475836 16573830 10.1186/1475-2840-5-6
21. Hattori Y Suzuki M Hattori S Kasai K Vascular smooth muscle cell activation by glycated albumin (amadori adducts) Hypertension 2002 39 22-28 10.1161/hy1201.097300 11799073
22. Muhlestein JB May HT Jensen JR Horne BD Lanman RB Lavasani F Wolfert RL Pearson RR Yannicelli HD Anderson JL The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: The DIACOR (Diabetes and Combined Lipid Therapy Regimen) study J Am Coll Cardiol 2006 48 396-401 10.1016/ j.jacc.2006.05.009 16843192
23. Ross R Atherosclerosis-an inflammatory disease N Engl J Med 1999 340 115-126 10.1056/NEJM199901143400207 9887164
24. Wilson AM Ryan MC Boyle AJ The novel role of C-reactive protein in cardiovascular disease: Risk marker or pathogen Int J Cardiol 2006 106-291 297 10.1016/j.ijcard.2005.01.068 16337036
25. Pfutzner A Forst T High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus Diabetes Technol Ther 2006 8 28-36 10.1089/dia.2006.8.28 16472048
26. Fonseca VA Theuma P Mudaliar S Leissinger CA Clejan S Henry RR Diabetes treatments have differential effects on nontraditional cardiovascular risk factors J Diabetes Complications 2006 20 14-20 10.1016/ j.jdiacomp.2005.05.009 16389162
27. Kimberly MM Cooper GR Myers GL An overview of inflammatory markers in type 2 diabetes from the perspective of the clinical chemist Diabetes Technol Ther 2006 8 37-44 10.1089/dia.2006.8.37 16472049
28. Pfutzner A Standl E Strotmann HJ Schulze J Hohberg C Lubben G Pahler S Schondorf T Forst T Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus Clin Chem Lab Med 2006 44 556-560 10.1515/CCLM.2006.108 16681424
29. Myint KM Yamamoto Y Sakurai S Harashima A Watanabe T Li H Takeuchi A Yoshimura K Yonekura H Yamamoto H Blockade of diabetic vascular injury by controlling of AGE-RAGE system Curr Drug Targets 2005 6 447-452 10.2174/1389450054021882 16026264
30. Fisman EZ Motro M Tenenbaum A Cardiovascular diabetology in the core of a novel interleukins classification: The bad, the good and the aloof Cardiovasc Diabetol 2003 2 11 212422 14525620 10.1186/1475-2840-2-11